Home
About
- Board of Directors
- Management
AQS Platform
Deoxymabs
Investors
News
Contact

Patrys advances RLS-2202 toward Phase 1 Clinical Trial

Patrys Limited

Patrys is a publicly-listed company focused on developing a clinical candidate for acute delirium and a novel antibody technology platform for cancer and inflammatory disease.

About Us

Newsletter

Get news and updates from Patrys delivered to your inbox.

Subscribe

Stay Connected

Keep up to date with the latest news from Patrys by following us on social media.

ASX
Privacy Policy

Menu